Immunization with rabies virus vector expressing foreign protein antigen

Patent metadata

Field	Value
Publication number	US-9889192-B2
Application number	US-201314430441-A
Country	US
Kind code	B2
Filing date	Sep 24, 2013
Priority date	Oct 1, 2012
Publication date	Feb 13, 2018
Grant date	Feb 13, 2018

Abstract

An immune response in a subject is elicited by a regiment comprising immunization with an attenuated recombinant rabies virus encoding at least one foreign protein antigen, and booster immunization with the at least one foreign protein antigen in a vehicle that does not contain adjuvant. The foreign protein antigen may comprise a prion protein antigen, a cancer-associated antigens, a viral antigen, a bacterial antigens, or a protozoal antigen. The prime/boost regimen produces predominantly IgG 2A/C and IgG 2B antibodies against the foreign protein antigen, indicating a TH1 response. Rabies virus attenuation may be provided, for example, by one or more mutations in the rabies glycoprotein gene which confers attenuation of pathogenicity.

First claim

The invention claimed is:

1. A method of eliciting an immune response in a subject, comprising the steps of:
(a) providing an attenuated recombinant rabies virus encoding for at least one foreign protein antigen operably linked to control sequences, wherein the foreign protein antigen is located between two G genes in the genome of said attenuated recombinant rabies virus and is not expressed in the structure of the recombinant virus; wherein said control sequences direct the expression of said foreign antigen in a suitable recipient cell infected by said virus; wherein the attenuated recombinant rabies virus contains a mutation wherein the amino acid 333 is glutamic acid and wherein the amino acid 194 is serine in the glycoprotein;
(b) infecting a recipient cell with said rabies virus into a recipient cell of said subject under conditions that permit the expression of said one or more foreign protein antigens by the recipient cell, thereby eliciting an immune response to said foreign protein antigen;
(c) boosting said immune response to said foreign protein antigen by administering to said subject said foreign protein antigen contained in a booster composition which is adjuvant-free; and
(d) generating a T cell and B cell response in said subject.

2. The method according to claim 1 wherein the foreign protein antigen comprises a prion protein antigen.

3. The method of claim 1 , wherein said foreign protein antigen comprises at least one antigen selected from the group consisting of cancer-associated antigens, viral antigens, bacterial antigens, and protozoal antigens.

4. The method according to claim 3 , wherein the cancer-associated antigen is selected from the group consisting of AIM-2, alphafetoprotein, bladder cancer-associated protein, breast carcinoma associated MAR-binding proteins p90 and p70, breast cancer-associated protein 3, carcinoembryonic antigen, CA-125, epithelial tumor antigen, c-erb/B2, gp100, HER-2, IL13Rα2, MAGE-1, MART-1, melanoma-associated antigens, MUC-1, MCU-2, prostate-associated antigen, abnormal products of p53, abnormal products of ras, survivin, tyrosinase, TRP-2 and tyrosine kinase 2.

5. The method according to claim 3 wherein the foreign protein antigen is a viral antigen.

6. The method according to claim 5 where the viral antigen is an antigen of a virus selected from the group consisting of cytomegalovirus, Dengue, Ebola virus, equine encephalitis virus, hepatitis virus, HIV, Hendra virus, herpes simplex virus, human papilloma virus, influenza, Japanese Encephalitis virus, neurotropic viruses, Nipah virus, Rift Valley Fever virus and West Nile Virus.

7. The method according to claim 6 , wherein the viral antigen is an antigen of Nipah virus G gene.

8. The method according to claim 3 wherein the foreign protein antigen is an antigen of a pathogen which is associated with chlamydia, diphtheria, pertussis, tetanus, tuberculosis, nontuberculous mycobacteria-associated disease, bacterial and fungal pneumonias, babesiosis, cholera, typhoid, plague, shigellosis, salmonellosis, Legionnaire's Disease, Lyme disease, malaria, hookworm, onchocerciasis, schistosomiasis, trypanosomiasis, leshmaniasis, giardiasis, amoebiasis, filariasis, borreliosis, or trichinosis.

9. The method according to claim 1 wherein the attenuated recombinant rabies virus comprises two or more G genes.

10. The method according to claim 9 wherein a nucleotide sequence encoding the at least one foreign protein antigen is located between two G genes in the genome of said attenuated recombinant rabies virus.

11. The method according to claim 1 wherein a nucleotide sequence encoding the at least one foreign protein antigen is located between the M and L genes in the genome of said attenuated recombinant rabies virus.

12. The method according to claim 1 , wherein the attenuated recombinant rabies virus encoding at least one foreign protein is introduced into a recipient cell of the subject without adjuvant.

13. The method according to claim 1 , wherein the adjuvant-free booster composition comprises saline or phosphate-buffered saline.

14. A kit for immunization of a subject comprising:
(a) a first composition comprising an attenuated recombinant rabies virus encoding for at least one foreign protein antigen operably linked to control sequences, wherein the foreign protein antigen is located between two G genes in the genome of said attenuated recombinant rabies virus and is not expressed in the structure of the recombinant virus; wherein said control sequences direct the expression of said foreign antigen in a suitable recipient cell infected by said virus; wherein the attenuated recombinant rabies virus contains a mutation wherein the amino acid 333 is glutamic acid and wherein the amino acid 194 is serine in the glycoprotein;
(b) a second composition comprising the at least one foreign protein antigen, wherein said second composition is adjuvant-free.

15. A kit according to claim 14 , wherein said first composition is adjuvant-free.

16. The kit according to claim 14 , wherein the at least one foreign protein antigen comprises a prion protein antigen, a cancer-associated antigen, a viral antigen, a bacterial antigen, or a protozoal antigens.

17. The kit according to claim 16 , wherein the cancer-associated antigen is selected from the group consisting of AIM-2, alphafetoprotein, bladder cancer-associated protein, breast carcinoma associated MAR-binding proteins p90 and p70, breast cancer-associated protein 3, carcinoembryonic antigen, CA-125, epithelial tumor antigen, c-erb/B2, gp100, HER-2, IL13Rα2, MAGE-1, MART-1, melanoma-associated antigens, MUC-1, MCU-2, prostate-associated antigen, abnormal products of p53, abnormal products of ras, survivin, tyrosinase, TRP-2 and tyrosine kinase 2.

18. The kit according to claim 16 wherein the viral antigen is an antigen of a virus selected from the group consisting of cytomegalovirus, Dengue, Ebola virus, equine encephalitis virus, hepatitis virus, HIV, Hendra virus, herpes simplex virus, human papilloma virus, influenza, Japanese Encephalitis virus, neurotropic viruses, Nipah virus, Rift Valley Fever virus and West Nile Virus.

19. The kit according to claim 16 wherein the foreign protein antigen is an antigen of a pathogen which is associated with chlamydia, diphtheria, pertussis, tetanus, tuberculosis, nontuberculous mycobacteria-associated disease, bacterial and fungal pneumonias, babesiosis, cholera, typhoid, plague, shigellosis, salmonellosis, Legionnaire's Disease, Lyme disease, malaria, hookworm, onchocerciasis, schistosomiasis, trypanosomiasis, leshmaniasis, giardiasis, amoebiasis, filariasis, borreliosis, or trichinosis.

20. The kit according to claim 14 wherein the attenuated recombinant rabies virus contains one or more mutations in the rabies glycoprotein gene which confers attenuation of pathogenicity.

Assignees

• Univ Jefferson

Inventors

• Dietzschold Bernhard
• Hooper Douglas Craig
• Faber Milosz

Classifications

• C07K14/005

  from viruses · CPC title

• C12N2760/18034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/18234

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/20143

  viral genome or elements thereof as genetic vector · CPC title

• C12N2760/20122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title